Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
WATERTOWN, Mass., Aug. 01, 2017 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of ocular sustained release drug products and technologies for eye diseases, today announced that Nancy Lurker, President and Chief Executive Officer, will present at the Canaccord Genuity 2017 Growth Conference at the InterContinental Boston in Boston, MA. The presentation is scheduled for Thursday, August 10, 2017, at 2:30pm Eastern Time.
A live audio and/or webcast and subsequent archived replay of pSivida’s presentation may be accessed via the Investors section of the Company’s website under “Resources - Events & Presentations” at www.psivida.com. The replay will be available for 90 days after the event.
About pSivida Corp.
pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the US and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis being independently developed. Two pivotal Phase 3 studies achieved their primary efficacy endpoint at six months of follow-up with statistical significance. pSivida's pre-clinical development program is focused on using its core platform technology Durasert™ to deliver drugs and biologics to treat uveitis, wet age-related macular degeneration, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.
Contact: EVC Group Michael Polyviou/Doug Sherk – Investors [email protected]; [email protected] 212.850.6020; 646-445-4800 Thomas Gibson – Media [email protected] 201-476-0322
